Verified peer comparison

ELV vs ABBV

Elevance Health, Inc. compared with AbbVie Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

ELV

Elevance Health, Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

ABBV

AbbVie Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

ELV: Managed Health Care

ABBV: Biotechnology

Upside lens

ELV: Pharmacy, behavioral-health and care-delivery services can grow within Elevance plans and with external clients. Disciplined pricing and product design can preserve margins as utilization changes. Scale in Medicaid and Medicare can support membership relationships when rates reflect care costs.

ABBV: Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry. Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology. Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

Risk lens

ELV: State rates may lag acuity changes after eligibility redeterminations, compressing margins. Higher outpatient, pharmacy or specialty-care use can exceed premium assumptions. Payment rules, risk adjustment and benefit mandates can alter product economics.

ABBV: Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition. Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand. U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.